Clinical Trials Logo

Medical Oncology clinical trials

View clinical trials related to Medical Oncology.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06097533 Not yet recruiting - Quality of Life Clinical Trials

Improvement of Quality of Life by Cannabinoids in Oncologic Patients

BELCANTO
Start date: December 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal is to explore whether the application of cannabis extract Avextra 10/10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. The primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the Edmonton Symptom Assessment System total symptom distress score (ESAS TSDS) at baseline and after 12±2 days.

NCT ID: NCT05423808 Not yet recruiting - Geriatrics Clinical Trials

Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients.

GerOnTe-TWOBE
Start date: June 2024
Phase: N/A
Study type: Interventional

The GerOnTe TWOBE study aims to evaluate the effectiveness of the GerOnTe intervention, consisting of a renewed, patient-centred, care pathway coordinated by an APN and supported by a Health Professional Consortium and IC Technology, compared to the current standard of care in the eight different Belgian and Dutch hospitals.

NCT ID: NCT02327806 Not yet recruiting - Medical Oncology Clinical Trials

The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance

Start date: January 2015
Phase: N/A
Study type: Interventional

Pulsed electromagnetic field therapy (PEMFT) is a reparative technique most commonly used in the field of orthopedics for the treatment of non-union fractures. The aim is to test the effect of the magnetic induction on brute force of treated muscle in oncological patients. Oncology patients were chosen as we assume that the ipmrovement will be more noticable in oncology patients than in a non-oncology, healthy subjects.